Alnylam Pharmaceuticals
ALNY
#581
Rank
A$53.83 B
Marketcap
$417.41
Share price
2.75%
Change (1 day)
66.10%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -$6.06

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$6.26. In 2022 the company made an earnings per share (EPS) of -$14.16 a decrease over its 2021 EPS that were of -$10.97.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$6.06-57.22%
2022-$14.1629.03%
2021-$10.97-3.36%
2020-$11.35-8.48%
2019-$12.407.67%
2018-$11.5239.74%
2017-$8.2412.94%
2016-$7.3038.84%
2015-$5.26-32.88%
2014-$7.83259.44%
2013-$2.18-31.25%
2012-$3.1752.94%
2011-$2.0730.77%
2010-$1.58-8.77%
2009-$1.7478.13%
2008-$0.98-70.78%
2007-$3.3499.09%
2006-$1.68-43.88%
2005-$2.99-82.33%
2004-$16.91-59.23%
2003-$41.47

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$2.59-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
$56.93-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-$11.93 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.41-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-$2.58-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.70-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$4.85-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-$3.05-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel